|
|
|
Company
|
|
Questcor Pharmaceuticals, Inc. |
|
Questcor Pharmaceuticals, Inc., formerly Cypros Pharmaceutical Corporation, is an integrated specialty pharmaceutical company focused on the development, acquisition and marketing of innovative, acute care and critical care hospital pharmaceutical products. The Company sells Glofil-125 and Inulin, both injectable drugs that assess kidney function by measuring glomerular filtration rate, and Ethamolin, an injectable drug that treats bleeding esophageal varices. The Company is manufacturing its proprietary topical triple antibiotic wound care product for its over-the-counter marketing partner, NutraMax Products, Inc., utilizing Questcor's patented DermaFlo drug delivery technology. On November 17, 1999, the Company completed its merger with RiboGene Inc. (RiboGene) and subsequently changed its name to Questcor Pharmaceuticals, Inc.
| Market Assistant |
 |
PrecisionAlert |
|
|
|
|
|
|
|
|
_web.gif)
